Alchemia raises $5m in share purchase plan
Wednesday, 14 December, 2005
Brisbane biopharma Alchemia (ASX:ACL) has successfully raised AUD$5 million, closing its share purchase plan heavily oversubscribed. Earlier this month the company raised $14.6 million through a share placement. The funds will be used to accelerate Alchemia's drug discovery program, specifically to progress anti-cancer drug candidate ACL16907 from preclinical status to the completion of phase II clinical trials in 2008, and to advance an eye-disease candidate for age-related macular degeneration to the end of phase I clinical trials by 2007-08.
It will also be used to help identify new preclinical candidates using Alchemia's drug discovery platform
The offer of up to 4,545 shares at $1.10 per share was made to all registered shareholders in Australia and New Zealand on November 3, and taken up by more than 65 per cent of eligible shareholders. At time of writing Alchemia shares were trading at $1.19.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
